Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines: revenue of $15.03B (+3% YoY) exceeded the $14.39B expected, while Adjusted Diluted EPS of $0.77 beat the $0.68 mean estimate. Strong performance in non-COVID products (+18% operational growth) was led by Eliquis and Padcev, offsetting a 95% collapse in Paxlovid sales. Management raised the FY26 revenue midpoint by $500M to $61.5B due to non-COVID strength, despite reaffirming EPS guidance to absorb a $0.10 impact from the Innovent transaction.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Pfizer(PFE) the Revenue is 15.03 B (+2.6%), Beat estimate;the EBIT is 5.288 B (-0.51%), Beat estimate;the EPS is -0.04 (-107.8%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
15.03B2.60%
14.39B1.81%
+0.65B4.41%
EBITExceed expectations
5.29B0.51%
5.02B5.48%
+0.26B4.97%
EPSMiss expectations
-0.04107.84%
0.448812.01%
-0.488895.83%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf